Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Parexel Intl Cp (PRXL)

Parexel Intl Cp (PRXL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,502,650
  • Shares Outstanding, K 51,120
  • Annual Sales, $ 2,442 M
  • Annual Income, $ 107,300 K
  • 60-Month Beta 0.79
  • Price/Sales 1.84
  • Price/Cash Flow N/A
  • Price/Book 7.09
  • Price/Earnings ttm 26.14
  • Earnings Per Share ttm 3.37
  • Most Recent Earnings 0.74 on 05/03/17
  • Next Earnings Date 10/25/17
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/17
See More
  • Average Estimate 0.89
  • Number of Estimates 8
  • High Estimate 0.96
  • Low Estimate 0.82
  • Prior Year 0.76
  • Growth Rate Est. (year over year) +17.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
87.69 +0.44%
on 09/07/17
88.10 -0.02%
on 09/29/17
+0.30 (+0.34%)
since 08/29/17
3-Month
86.85 +1.42%
on 06/30/17
88.10 -0.02%
on 09/29/17
+1.18 (+1.36%)
since 06/29/17
52-Week
51.16 +72.17%
on 11/11/16
88.10 -0.02%
on 09/29/17
+19.58 (+28.58%)
since 09/29/16

Most Recent Stories

More News
The global bioanalytical testing services market is projected to reach USD 3.7 billion by 2025 from USD 2.1 billion in 2020, at a CAGR of 11.8%

, /PRNewswire/ --

ERRFY : 17.7000 (-14.86%)
ICLR : 183.14 (+2.30%)
LH : 180.99 (+1.77%)
PRXL : 88.08 (-0.02%)
PRAH : 97.29 (+1.28%)
SGSOF : 2,650.0000 (+1.21%)
New Reports And Data Report Explores Impact of COVID-19 Outbreak on Diabetic Retinopathy Market | Bayer AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., Regeneron Pharmaceuticals Inc., Novartis AG, etc

ABT : 103.45 (+2.51%)
ALIM : 5.05 (unch)
AMPE : 0.9451 (+12.51%)
BAYRY : 15.6900 (-1.26%)
GSK : 37.80 (+1.12%)
MRK : 82.93 (-0.26%)
NVS : 87.11 (+0.94%)
PRXL : 88.08 (-0.02%)
PFE : 36.05 (+0.81%)
REGN : 574.06 (+2.98%)
VRX.TO : 30.80 (-3.33%)
New Reports And Data Report Explores Impact of COVID-19 Outbreak on Diabetic Retinopathy Market | Bayer AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., Regeneron Pharmaceuticals Inc., Novartis AG, etc

MMM : 160.27 (-0.09%)
ABT : 103.45 (+2.51%)
ALIM : 5.05 (unch)
AMPE : 0.9451 (+12.51%)
AHKSF : 8.8500 (-0.56%)
BAYRY : 15.6900 (-1.26%)
MRK : 82.93 (-0.26%)
NVS : 87.11 (+0.94%)
PLL : 11.00 (+32.53%)
PRXL : 88.08 (-0.02%)
PFE : 36.05 (+0.81%)
REGN : 574.06 (+2.98%)
VRX.TO : 30.80 (-3.33%)
Parexel Launches Enhanced Integrated Functional Service Provider Model to Drive Delivery of Innovative Clinical Research Partnerships

Parexel, a leading provider of solutions to accelerate the development and delivery of innovative new therapies to market to improve world health, from Clinical through to Commercialization, today launched...

PRXL : 88.08 (-0.02%)
Cato Research Appoints Life Sciences Leader And Innovator To Executive Chairman

Cato Research, LLC (CATO), a global provider of regulatory and clinical research services, announced today that its board of directors has appointed Mark Goldberg, M.D. to executive chairman, effective...

IFCPF : 9.4246 (unch)
PRXL : 88.08 (-0.02%)
PAREXEL Ranked #1 Among Global CROs for Leadership in Phase II/III Clinical Research in Prominent Annual ISR CRO Quality Benchmark Survey

--Also named a 2019 CRO Leadership Award Winner

PRXL : 88.08 (-0.02%)
PAREXEL Expands Oncology Expertise Through FDA and Medical Oncologist Appointments

PAREXEL International Corporation, a leading innovator of global biopharmaceutical services, today announced several new appointments that will enhance the company's oncology expertise as...

PRXL : 88.08 (-0.02%)
Trade PRXL with:

Business Summary

Parexel International Corporation is one of the largest biopharmaceutical outsourcing organizations in the world, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. With...

See More

Key Turning Points

2nd Resistance Point 88.11
1st Resistance Point 88.10
Last Price 88.08
1st Support Level 88.07
2nd Support Level 88.05

See More

52-Week High 88.10
Last Price 88.08
Fibonacci 61.8% 73.99
Fibonacci 50% 69.63
Fibonacci 38.2% 65.27
52-Week Low 51.16

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar